Multiple sclerosis drug shows promising efficacy
The multiple sclerosis drug is showing promising efficacy in fighting relapses and reducing fatigue.
Back in March 2001, the US Food and Drug Administration approved a drug called ponosimod for use in adult patients with various types of multiple sclerosis. Only now there are research data that show that some drug reduces the number of relapses of the disease and can reduce fatigue - one of the characteristic symptoms of multiple sclerosis.
The respected scientific journal JAMA Neurology has found that ponesimod is more effective in fighting fatigue in multiple sclerosis than another commonly used drug called teriflunomide. It is superior to teriflunomide in reducing relapse rates and reducing the risk of new or existing lesions of myelin found on magnetic resonance imaging.
As reported by everydayhealth.com, ponesimod is used for various types of multiple sclerosis, including the most common relapsing remitting disease and active secondary progressive, which is the most severe. It is not accompanied by remissions and steadily leads to the disability of patients. It is people with this form of multiple sclerosis who show the appearance of new lesions of the myelin layer on MRI scans. Ponesimod must be taken once a day, treatment begins with a period of 14 days, then the doses are increased.
